ライフサイエンスコーパス: CRF receptor

1 ated by mechanisms other than the identified CRF receptors.

2 factor (CRF) and CRF-related peptides on two CRF receptors.

3 sidered to be a second endogenous ligand for CRF receptors.

4 s to neurodegeneration through activation of CRF receptors.

5 sing factor (hCRF) C-terminal 33 residues to CRF receptors.

6 inding of the CRF C-terminus 30 residues, to CRF receptors.

7 a-helical conformation when interacting with CRF receptors.

8 elatively independently of the activation of CRF receptors.

9 nificantly blocking both brain and pituitary CRF receptors.

10 slightly altered by blockade of hypothalamic CRF receptors.

11 rats and at determining the role of central CRF receptors.

12 ceptor activation and, to a lesser extent on CRF receptors.

13 receptors (GPCRs) known as type-1 and type-2 CRF receptors.

14 st of corticotropin (ACTH) releasing factor (CRF) receptors.

15 The CRF receptor 1 (CRF-R1) antagonist, NBI-27914 (50-100 mi

16 endent and requires the downstream action of CRF receptor 1 (CRF-R1), suggesting that dopamine induce

17 We previously demonstrated that CRF receptor 1 (CRF1) neurons comprise a specific compon

18 ctions are mediated through their receptors, CRF receptor 1 (CRFR1) and CRFR2, found throughout the C

19 ment increases Abeta production and triggers CRF receptor 1 (CRFR1) and gamma-secretase internalizati

20 y, pharmacological experiments revealed that CRF receptor 1 and protein kinase A pathways were newly

21 to (1) determine the effect of the selective CRF receptor 1 antagonist (CRF(1)) GW876008 relative to

22 Consistent with this, the CRF receptor 1 antagonist, antalarmin, prevented swim-st

23 eceptor 2 antagonist astressin-2B, but not a CRF receptor 1 antagonist, reversed the inhibitory effec

24 We showed previously that CRF receptor 1-expressing (CRF1+) neurons in the CeA are

25 asing factor (CRF) exerts its action through CRF receptors 1 and 2 (CRF-R1 and CRF-R2).

26 -protein-coupled receptors of the B1 family, CRF receptors 1 and 2 (CRF-R1 and CRF-R2alpha,beta).

27 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target for the treatment of

28 dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intact hypothalamic-pit

29 ng, which was prevented by antagonism of the CRF receptor-1 (CRF-R1), and was mimicked by CRF-R1 agon

30 relapse, a subsequent experiment found that CRF receptor-1 (CRF1) blockade in the AId similarly redu

31 Development of CRF receptor-1 (CRFr1) antagonists has been a focus of n

32 ctor (CRF) actions at both of its receptors, CRF receptor-1 and CRF receptor-2.

33 g elevations in tryptophan hydroxylase-2 and CRF receptor-1 expression and concordant increases in be

34 by increased corticotropin releasing factor (CRF) receptor-1 expression and signalling, which modulat

35 This effect involves CRF receptor 2 (CRF-R2) and activation of the phospholip

36 However, LS injections of CRF receptor 2 antagonist astressin-2B, but not a CRF re

37 ides similarly modulate maternal defense via CRF receptor 2, and that LS is a critical site for the n

38 ne release are prevented by VTA infusions of CRF-receptor 2 (CRF-R2) but not CRF-R1 antagonists.

39 Mice deficient in CRF receptor-2 (R2KO) were used as a model of maladaptiv

40 at both of its receptors, CRF receptor-1 and CRF receptor-2.

41 of the first extracellular domain (ECD1) of CRF receptor 2beta (CRF-R2beta), free and complexed with

42 nal extracellular domain (ECD1) of the mouse CRF receptor 2beta, which is the major ligand recognitio

43 These data indicate that CRF receptors act in concert to increase the magnitude o

44 The current studies examined whether CRF receptor activation in the PFC modulates cognitive f

45 hese results support a propinquity effect in CRF receptor activation, in which the amino-terminal por

46 lexed to the CRF-BP and thus unavailable for CRF receptor activation.

47 ated actions in the vBNST also require local CRF receptor activation.

48 e effects of corticotropin-releasing factor (CRF) receptor activation and antagonism on intracranial

49 Corticotropin-releasing factor (CRF) receptor activation within the basolateral amygdala

50 Reduced corticotropin releasing factor (CRF) receptor activity and hypothalamic-pituitary-adrena

51 nd defecation) while oCRF(9-33)OH (devoid of CRF receptor affinity) showed neither effects.

52 These results suggest that CRF receptor agonist administration is capable of produc

53 n of anorexia is a well documented effect of CRF receptor agonist administration, the central sites a

54 d for the effects on ICSS of the competitive CRF receptor agonist h/rCRF (0-5.0 microg, i.c.v.), the

55 r agonist h/rCRF (0-5.0 microg, i.c.v.), the CRF receptor agonist urocortin (0-5.0 microg, i.c.v.), a

56 Corticotropin-releasing factor (CRF) receptor agonist and CRF binding-protein (CRF-BP) l

57 In marked contrast to the effects of a CRF-receptor agonist, the CRF-BP ligand inhibitor did no

58 To develop selective CRF receptor agonists, we have scanned the sequence -Gln

59 components of the HPA axis, such as CRF and CRF receptors, along with POMC gene and gene products.

60 To further elucidate the roles of both CRF receptors and determine their interaction in behavio

61 However, CRF receptors and neuronal elements are present in many

62 blastoma cell line for functional studies on CRF receptors and suggest that CRF may play a regulatory

63 lting in down-regulation of adenohypophyseal CRF receptors and symptoms of depression and anxiety.

64 ess responses by their interactions with the CRF receptors and the CRF-binding protein (CRF-BP).

65 Urocortin III is selective for type 2 CRF receptors and thus represents another potential endo

66 Using the corticotropin-releasing factor (CRF) receptor and the thrombin receptor as a model, we p

67 ts that release CRF into the VTA, activating CRF receptors, and promoting cocaine use.

68 ut relatively impotent in blocking pituitary CRF receptors; and (2) astressin, inverted question mark

69 Therefore, we investigated the effects of CRF receptor antagonism within the dRN on social anxiety

70 particular, administration of a competitive CRF receptor antagonist [0.2, 1 or 5 microg intracerebro

71 st urocortin (0-5.0 microg, i.c.v.), and the CRF receptor antagonist [D-Phe(12), Nle(21,38), C(alpha)

72 The CRF receptor antagonist [D-Phe12,Nle(21,38)C(a)MeLeu(37)

73 In a third experiment, the CRF receptor antagonist alpha-helical CRF(9-41) administ

74 to the BLA either alone or together with the CRF receptor antagonist alpha-helical CRF(9-41) immediat

75 as blocked by treatment with the competitive CRF receptor antagonist alpha-helical CRF9-41 and with t

76 In addition, the putative CRF receptor antagonist alpha-helical CRF9-41 dose-depen

77 ntral tegmental area (VTA), a site where the CRF receptor antagonist antalarmin prevents the reinstat

78 nificantly reduced following infusion of the CRF receptor antagonist D-Phe CRF((12-41)) into the BNST

79 arena, rats were infused with vehicle or the CRF receptor antagonist d-Phe-CRF((12-41)) (50 or 500 ng

80 lar (1000 ng) injections of the nonselective CRF receptor antagonist D-Phe-CRF(12-41) decreased frust

81 inase B (TrKB) inhibitor k-252a, but not the CRF receptor antagonist D-Phe-CRF(12-41).

82 lly blocked by concurrent treatment with the CRF receptor antagonist D-Phe-CRF(12-41).

83 i.c.v.) was blocked by pretreatment with the CRF receptor antagonist d-PheCRF(12-41) (3.0 microg, i.c

84 t cell-deficient mice and was blocked by the CRF-receptor antagonist, Antalarmin.

85 ely absent after exposure to the competitive CRF receptor antagonists alpha-helical CRF(9-41) or rat/

86 CRF receptor antagonists are very effective in reversing

87 These data suggest that CRF receptor antagonists could provide a potential treat

88 Furthermore, these results imply a role for CRF receptor antagonists in the prevention and treatment

89 ned the effects of two different competitive CRF receptor antagonists on the expression of conditione

90 Two pharmacologically distinct CRF receptors are distributed in different brain regions

91 In contrast, functional pituitary CRF receptors are essential for the ACTH response to the

92 of the amygdala (CeA), despite the fact that CRF receptors are more densely distributed in BLA than i

93 saicin-sensitive primary afferents and brain CRF receptors are part of the pathways and biochemical c

94 hat corticotropin-releasing factor (CRF) and CRF receptors are prominent in the PFC, the cognitive ef

95 Corticotropin-releasing factor (CRF) receptors are found in stress-related regions, incl

96 Because corticotropin-releasing factor (CRF) receptors are implicated, we compared CRF receptor

97 ists for the corticotropin releasing factor (CRF) receptors are new tools to investigate stress-relat

98 nding peptide binding and specificity by the CRF receptors as well as a template for designing potent

99 dent and provides important insight into the CRF receptor-associated circuitry that likely underpins

100 CRF receptor autoradiography was performed in rat tissue

101 agonists of corticotrophin-releasing factor (CRF) receptors bind to the receptor by a two-site mechan

102 The synthesis and CRF receptor binding affinities of several new series of

103 (CRF) receptors are implicated, we compared CRF receptor binding in pre- and postpubertal rats.

104 iographic studies to map the distribution of CRF receptor binding sites in the mouse brain.

105 In each brain area, CRF receptor binding was sexually dimorphic, but no two

106 tor (CRF)-immunoreactive fibers and contains CRF receptor-binding sites, suggesting that endogenous C

107 with biological responses mediated by brain CRF receptors, but relatively impotent in blocking pitui

108 ing protein (CRF-BP), a moiety distinct from CRF receptors, but which is nonetheless capable of bindi

109 irect endogenous mechanism for activation of CRF receptors by new mammalian members of the CRF family

110 These results suggest that the pituitary CRF receptor can discriminate between slightly different

111 d urocortin 1 (Ucn1), which bind to both the CRF receptors CRF-R1 and CRF-R2, and the urocortins 2 (U

112 e Y (NPY), glucocorticoid receptor (GR), and CRF receptor (CRF-R) in selected brain regions.

113 Ucn II binds selectively to the type 2 CRF receptor (CRF-R2), with no appreciable activity on C

114 III is a high-affinity ligand for the type 2 CRF receptor (CRF-R2).

115 proposed as an endogenous ligand for type 2 CRF receptors (CRF-R2).

116 factor (CRF) activates neurons that express CRF receptors (CRF-Rs), we followed the kinetics and dis

117 ve disorders, and have high densities of the CRF receptors CRF1 and CRF2.

118 ow sex differences in the association of the CRF receptor (CRF1) with the Gs protein and beta-arresti

119 The corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) are crucial mediators of

120 mpared the telencephalic distribution of the CRF receptors, CRF1 and CRF2 , and two of their ligands,

121 wo different corticotropin-releasing factor (CRF) receptors, CRF1 and CRF2, have been identified in r

122 (Ucn 1) with high affinity, thus preventing CRF receptor (CRFR) activation.

123 most of these are lacking or impoverished in CRF receptor (CRFR) expression.

124 ral nucleus of the amygdala (CeA), where the CRF receptor (CRFr) plays an important role in anxiety-

125 d -III signal by activating their receptors, CRF receptors (CRFR)1 and -2, to maintain homeostasis th

126 The corticotropin-releasing factor (CRF) receptor CRFR2 is expressed widely in peripheral ti

127 factor (CRF) family, and its cognate type 2 CRF receptor (CRFR2) are highly expressed in skeletal mu

128 The type 2 CRF receptor (Crfr2) marks a subset of LS neurons whose

129 cologic blockade of its receptor, the type 2 CRF receptor (CRFR2), attenuated high but not low glucos

130 ) family, binds with high affinity to type 2 CRF receptors (CRFR2) on cardiomyocytes and confers prot

131 eceptor signaling or compensatory changes in CRF receptor density within these structures.

132 routinely used for the study of transfected CRF receptors do express endogenous CRF1 mRNA with splic

133 Corticotropin-releasing factor (CRF) receptors encoded by two distinct genes have recent

134 Thus, eight CRF receptor-expressing areas displayed eight distinct s

135 Although the cellular distribution of CRF receptor expression has been well characterized at t

136 Both of the characterized members of the CRF receptor family (CRF1 and CRF2), are found in the am

137 The neuroanatomic distribution of this CRF receptor family member is consistent with roles in m

138 data reinforce the importance of the ECD1 of CRF receptors for ligand recognition and raise the inter

139 icotropin-releasing factor (CRF) and altered CRF receptor function.

140 nergic, serotonergic, histamine, opiate, and CRF receptors had no effect, but those for adrenergic an

141 Corticotropin-releasing factor (CRF) receptors have been reported to play a role in toni

142 Results demonstrate a critical role of CRF receptors in BNST in stress-induced binge eating in

143 Here, we review the role of CRF receptors in both the brain and the gut as part of k

144 These data show that CRF receptors in CeA and LSMLN synapses exert and mainta

145 activation of pituitary and/or hypothalamic CRF receptors in mediating the stimulatory effect of EtO

146 ctural evidence for a primary involvement of CRF receptors in modulation of the postsynaptic excitabi

147 downregulation and desensitization of cloned CRF receptors in murine fibroblast cells (Ltk-) stably t

148 drive leading to downregulation of pituitary CRF receptors in Neo-A animals.

149 e and accurate available tool for localizing CRF receptors in rodent brain.

150 We also assessed the role of CRF receptors in the bed nucleus of the stria terminalis

151 Therefore, AT(1) and CRF receptors in the CeA contribute to hemodynamic respo

152 stems and may also support an involvement of CRF receptors in the development of depression such that

153 9, 12-15, 18, 19, 22-26, 28, 31) had k(i) to CRF receptors in the high picomolar and low nanomole ran

154 These results implicate the BNST CRF receptors in the mechanism of coping with stress.

155 in, a novel peptide activating both types of CRF receptors in vitro, but with preferential affinity f

156 Further examination of CRF receptors in vole species may reveal a novel role fo

157 f functional corticotropin-releasing factor (CRF) receptors in IMR-32 neuroblastoma cells.

158 xpression of corticotropin-releasing factor (CRF) receptors in the guinea pig enteric nervous system.

159 he levels of corticotropin-releasing factor (CRF) receptors in the serotonergic dorsal raphe nucleus

160 himera in which the N-terminal domain of the CRF receptor is replaced by the amino-terminal 16 residu

161 The CRF receptor is widely expressed across a variety of cel

162 Genetic variance in CRF receptors is linked to altered risk for stress disor

163 ion that contains both CRF-ergic neurons and CRF receptors is the midbrain periaqueductal gray (PAG).

164 CP-154,526 binds with high affinity to CRF receptors (Ki < 10 nM) and blocks CRF-stimulated ade

165 ists of the corticotrophin releasing factor (CRF) receptor markedly inhibit experimentally induced ex

166 The results also suggest that CRF receptors may provide novel targets in affective dis

167 calcium activated by postsynaptic Gs-coupled CRF receptors may represent a fundamental mechanism by w

168 fic developmental and physiological roles of CRF receptor mediated pathways.

169 Both corticosterone and central CRF receptors modulate pair bonding in the monogamous pr

170 Inhibition of endogenous CRF receptors or neuronal activity blocked the effects o

171 )) and sauvagine showed some selectivity for CRF receptors other than that responsible for ACTH secre

172 dentify several brain regions with conserved CRF receptor patterns across rodent and primate species,

173 nteresting implications for the evolution of CRF receptor patterns and behavior.

174 brain regions with phylogenetically plastic CRF receptor patterns, and have interesting implications

175 a large group of selective and nonselective CRF receptor peptide agonists will facilitate the develo

176 rn blot analysis of cultured BMEC identified CRF receptor protein; stimulation with CRF, or it struct

177 in 1 and 3, anxiogenic peptides that bind to CRF receptors, reduce maternal aggression in lactating m

178 Corticotropin-releasing factor (CRF) receptors represent one of the primary sites for ne

179 These data support a new model of respective CRF receptor roles in stress-related behavior such that,

180 the first extracellular domain (ECD1) of the CRF receptor(s) comprises the major ligand binding site

181 agonists will facilitate the development of CRF receptor selective drugs.

182 havioral effects may be mediated by enhanced CRF receptor signaling or compensatory changes in CRF re

183 These data indicate that increased CRF receptor signalling within a VTA-IPN-MHb circuit tri

184 As expected, blockade of pituitary CRF receptors significantly blunted EtOH-induced ACTH se

185 and validated as a high-affinity ligand for CRF receptor studies.

186 stigated the functional significance of this CRF receptor subtype in anxiety-like and memory processe

187 The CRF receptor subtype mediating the colonic and gastric m

188 antagonists, administered systemically, and CRF receptor subtype nonspecific antagonists, administer

189 f the present study were to characterize the CRF receptor subtypes (CRF-R1 and -R2) and cellular mech

190 biochemically and pharmacologically distinct CRF receptor subtypes (CRFR1 and CRFR2) have been descri

191 ults indicate a differential role of central CRF receptor subtypes in the colonic stimulatory and gas

192 The concept that multiple CRF receptor subtypes in the DRN facilitate distinct cop

193 v.) on gastric and colonic motility, and the CRF receptor subtypes involved and their role in colonic

194 We investigated the CRF receptor subtypes involved in gastric postoperative

195 Two distinct CRF receptor subtypes, CRFR1 and CRFR2, are thought to m

196 function through interaction with different CRF receptor subtypes.

197 Corticotropin-releasing factor (CRF) receptor subtypes 1 and 2 have been implicated in r

198 ation of two corticotropin-releasing factor (CRF) receptor subtypes.

199 fibers and also contained immunolabeling for CRF receptor, suggesting that c-fos-expressing neurons i

200 administration, the function of DA(1/5) and CRF receptors switched from inhibitory to excitatory.

201 esults show that sex differences pervade the CRF receptor system in juvenile and adult rats, and the

202 prevented by pre-stress administration of a CRF receptor type 1 (CRF(1)) antagonist.

203 for the immediate early gene NGFI-B and for CRF receptor type 1 (CRF-R(1)) in the parvocellular port

204 The differential roles for CRF receptor type 1 (CRF-R1) and CRF-R2 in stress-induce

205 y of serotonin neurotransmission through the CRF receptor type 1 (CRF-R1).

206 nal through the activation of two receptors, CRF receptor type 1 (CRFR1) and type 2 (CRFR2), both of

207 The CRF receptor type 1 (CRFR1) is considered the primary an

208 We demonstrate the presence of CRF receptor type 1 (CRFR1) on primary beta cells and sh

209 rsy, however, concerning the contribution of CRF receptor type 1 (CRFR1) to this effect and whether C

210 that were blocked by central infusion of the CRF receptor type 1 antagonist, antalarmin.

211 erging evidence also links the activation of CRF receptors type 1 and type 2 with stress-related alte

212 (NT) of the corticotropin releasing factor (CRF) receptor type 1 (R1) were studied by use of murine

213 atement was blocked by administration of the CRF-receptor type 1 (CRF-R1) antagonist antalarmin (500

214 vation of the serotonergic dorsal raphe, (2) CRF-Receptor type 1 (CRF-R1) in the dorsal raphe, (3) Ur

215 al hydrate-anesthetized rats and the role of CRF receptors using the nonselective CRF(1)/CRF(2) antag

216 The role of pituitary CRF receptors was shown by the ability of i.v. injected

217 The importance of hypothalamic CRF receptors was tested by injecting alpha-hel ant. int

218 that is devoid of intrinsic activity at the CRF receptors, was used as control peptide.

219 Expression levels of CRF receptors were measured in the amygdala nuclei and B

220 omized rats, suggesting that a proportion of CRF receptors were occupied before CRF administration, a

221 Corticotropin-releasing factor (CRF) receptors-which bind the hormone CRF as well as rel

222 light recent advances in the interactions of CRF receptors with other GPCRs and non-GPCR proteins and